---
title: Lilly Endowment Sold Eli Lilly Stock Worth Over $111B in Career Form 4 Value — and December 2025 Was Just the Latest Window
type: news
slug: lilly-endowment-sold-eli-lilly-stock-december-2025
canonical_url: https://13finsight.com/news/lilly-endowment-sold-eli-lilly-stock-december-2025
published_at: 2026-03-09T18:23:47.848Z
updated_at: 2026-03-23T07:03:48.631Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 246
locale: en
source: 13F Insight
---

# Lilly Endowment Sold Eli Lilly Stock Worth Over $111B in Career Form 4 Value — and December 2025 Was Just the Latest Window

> Lilly Endowment, the 10%-plus owner of Eli Lilly, has reported $111B+ in career Form 4 sell transactions. The December 2025 filing continues decades of systematic diversification.

What HappenedLilly Endowment Inc., the Indianapolis-based private foundation and 10%-plus beneficial owner of Eli Lilly & Co (LLY), filed its latest Form 4 with transactions dated December 29, 2025. Lilly Endowment has been a systematic seller of LLY stock for decades, with career Form 4 filings reporting over $111.8 billion in cumulative sell value across 10,747 transactions.Why It MattersLilly Endowment is one of the largest private foundations in the United States, with assets exceeding $50 billion. The foundation was created by the Lilly family and historically held a concentrated position in Eli Lilly stock. For decades, it has been gradually diversifying — selling LLY shares and redeploying the proceeds into grants and a more diversified investment portfolio.The selling is not a signal about Eli Lilly’s business prospects. It is mandated by the foundation’s fiduciary duty to diversify and by IRS rules requiring minimum annual distributions. The $111B+ career sell figure reflects the combination of volume (10,747 transactions) and Eli Lilly’s enormous stock price appreciation over decades.ContextEli Lilly has been one of the best-performing large-cap pharmaceutical stocks, driven by its GLP-1 weight-loss drug (tirzepatide/Mounjaro) and Alzheimer’s treatment pipeline. The stock traded above $1,000 per share in late 2025. Despite decades of selling, Lilly Endowment remains a significant shareholder due to the stock’s price appreciation outpacing the foundation’s sell rate.What to WatchLilly Endowment’s quarterly Form 4 filings for continued systematic sellingEli Lilly’s GLP-1 market share trajectory and pipeline updatesWhether the foundation’s LLY concentration continues to decrease or stabilizes

---

Source: 13F Insight — https://13finsight.com/news/lilly-endowment-sold-eli-lilly-stock-december-2025
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-23T07:03:48.631Z